Wellington Management Group LLP filed an amended beneficial ownership statement with the SEC on November 16, 2026, disclosing that it and affiliated entities collectively hold 8,094,339 shares of Zenas Biopharma, Inc. common stock, representing 12.4% of the class as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Wellington Management Group LLP reported 8,094,339 shares of Zenas Biopharma common stock beneficially owned in aggregate.
  • Percent of class: The aggregate position represents 12.42% of the outstanding class of common stock, according to the filing.
  • Shared voting power: Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP each reported shared voting power over 7,705,121 shares.
  • Shared dispositive power: The same three entities each reported shared dispositive power over 8,094,339 shares; Wellington Management Company LLP reported shared dispositive power over 7,891,827 shares.
  • No sole voting or dispositive power: All reporting persons disclosed 0 shares subject to sole voting or sole dispositive power.
  • Notable client interest: The filing identifies Vanguard Health Care Fund as the one known client with more than 5% rights to receive dividends or proceeds from the sale of the reported securities.
  • Triggering date: The event requiring the filing occurred on September 30, 2026.

Wellington's Ownership Structure in Zenas Biopharma

According to the filing, the reported shares are held of record by clients of one or more investment advisers directly or indirectly owned by Wellington Management Group LLP, a Massachusetts-based parent holding company. The advisory subsidiaries identified in the filing include Wellington Management Company LLP, Wellington Management Canada LLC, Wellington Management Singapore Pte Ltd, Wellington Management Hong Kong Ltd, Wellington Management International Ltd, Wellington Management Japan Pte Ltd, and Wellington Management Australia Pty Ltd, each classified as an investment adviser.

The filing describes the ownership chain as follows: Wellington Investment Advisors Holdings LLP controls, directly or indirectly through Wellington Management Global Holdings, Ltd., the investment adviser subsidiaries. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP, which in turn is owned by Wellington Management Group LLP. Zenas Biopharma, Inc., the issuer of the reported securities, is a biopharmaceutical company listed on NASDAQ:ZBIO, with principal executive offices located at 1000 Winter St, North Building, Suite 1200, Waltham, MA, according to the filing.

The filing certifies that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Wellington Management Company LLP, classified as an investment adviser, reported shared voting power over 7,697,151 shares and shared dispositive power over 7,891,827 shares, figures that differ modestly from the totals reported at the parent holding company level.

What Was Disclosed

Wellington Management Group LLP and three affiliated entities filed an amended beneficial ownership statement covering 8,094,339 shares of Zenas Biopharma, Inc. common stock (CUSIP 98937L105), equal to 12.42% of the class, with Vanguard Health Care Fund named as the one client with rights exceeding 5% of the class.